Table 1 Clinical prognostic features of HGSC patients
Prognostic factors | Cases (%) | Univariate Pa | Multivariate | |
|---|---|---|---|---|
HR (95% CI) | Pb | |||
Age (years) | Â | 0.281 | Â | 0.495 |
  ≤ 57 (median) | 57(50.4) |  | 1.000 |  |
  > 57 (median) | 56(49.6) |  | 1.010(0.982–1.037) |  |
FIGO Stage | Â | 0.002 | Â | 0.047 |
 Early(I + II) | 17(15.0) |  | 1.000 |  |
 Late(III + IV) | 96(85.0) |  | 3.241(1.065–10.879) |  |
Residual tumor (cm) | Â | 0.042 | Â | 0.543 |
  ≤ 1 | 104(92.0) |  | 1.000 |  |
  > 1 | 9(8.0) |  | 1.300 (0.558–3.027) |  |
Ascites | Â | 0.085 | Â | 0.690 |
 No | 11(9.7) |  | 1.000 |  |
 Yes | 102(90.3) |  | 1.280(0.380–4.311) |  |
Endometriosis | Â | 0.140 | Â | 0.568 |
 No | 101(89.4) |  | 1.000 |  |
 Yes | 12(10.6) |  | 1.245(0.586–2.647) |  |
Chemotherapeutic response | Â | 0.000 | Â | 0.000 |
 Platinum sensitive | 77(72.0) |  | 1.000 |  |
 Platinum resistant | 30(28.0) |  | 3.573(2.056–6.210) |  |